Media coverage about Bellicum Pharmaceuticals (NASDAQ:BLCM) has been trending somewhat positive this week, according to Alpha One Sentiment. Alpha One, a subsidiary of Accern, identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Alpha One ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Bellicum Pharmaceuticals earned a news sentiment score of 0.08 on Alpha One’s scale. Alpha One also gave news stories about the biopharmaceutical company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media headlines that may have effected AlphaOne’s rankings:
- Bellicum Pharmaceuticals : Announces Clinical Presentations at the 22nd Congress of the European Hematology Association (4-traders.com)
- The Cantor Fitzgerald Reaffirms “Overweight” Rating for Bellicum Pharmaceuticals Inc (BLCM) – BangaloreWeekly (bangaloreweekly.com)
- Bellicum Pharma (BLCM) Reports Clinical Presentations at EHA – StreetInsider.com (streetinsider.com)
- Bellicum Pharmaceuticals Announces Management Changes – GlobeNewswire (press release) (globenewswire.com)
A number of analysts have issued reports on BLCM shares. Cantor Fitzgerald set a $32.00 target price on Bellicum Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, February 23rd. Jefferies Group LLC reiterated a “buy” rating and issued a $22.00 price objective on shares of Bellicum Pharmaceuticals in a research report on Monday, February 27th. Wells Fargo & Co assumed coverage on Bellicum Pharmaceuticals in a research report on Wednesday, March 8th. They issued an “outperform” rating and a $29.50 price objective for the company. Finally, Zacks Investment Research upgraded Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, March 16th. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $26.81.
Bellicum Pharmaceuticals (NASDAQ:BLCM) traded up 3.25% during midday trading on Friday, hitting $12.70. The stock had a trading volume of 177,310 shares. The company has a 50-day moving average of $12.99 and a 200-day moving average of $14.50. The stock’s market cap is $420.41 million. Bellicum Pharmaceuticals has a 1-year low of $9.37 and a 1-year high of $23.11.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.70) by $0.10. The business had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.09 million. Bellicum Pharmaceuticals had a negative return on equity of 49.65% and a negative net margin of 19,399.12%. The business’s revenue for the quarter was up 39.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.56) earnings per share. Equities research analysts forecast that Bellicum Pharmaceuticals will post ($2.84) EPS for the current year.
In other Bellicum Pharmaceuticals news, major shareholder Bros. Advisors Lp Baker purchased 166,666 shares of the stock in a transaction on Friday, March 24th. The stock was acquired at an average cost of $12.00 per share, with a total value of $1,999,992.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 23.30% of the company’s stock.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
Receive News & Ratings for Bellicum Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.